Literature DB >> 9885898

Expression of a CD3 epsilon transgene in CD3 epsilon(null) mice does not restore CD3 gamma and delta expression but efficiently rescues T cell development from a subpopulation of prothymocytes.

N Wang1, B Wang, M Salio, D Allen, J She, C Terhorst.   

Abstract

The TCR-associated CD3 complex consists of four subunits, i.e. CD3 gamma, delta, epsilon and zeta, which are expressed very early in T cell development prior to the expression of the TCR and the pre-TCR alpha chain. It is unclear whether the expression of each CD3 protein is independent of, or is influenced by, other CD3 subunits. To study whether CD3 epsilon regulates expression of CD3 gamma and delta genes, we generated a strain of CD3 epsilon-deficient mice termed CD3 epsilon(delta P/delta P) (epsilon(delta P)), in which the promoter of CD3E was disrupted, and subsequently reconstituted these mice with a CD3 epsilon transgene. In the epsilon(delta P) mice, T cell development is arrested at the double-negative stage and targeting the CD3 epsilon gene caused severe inhibition of CD3 gamma and delta gene expression. Introduction of the CD3 epsilon transgene did not restore CD3 gamma and delta expression. However, a very small fraction of prothymocytes that expressed CD3 gamma and delta was rescued upon reconstitution of the CD3 epsilon transgene. Remarkably, this rescue led to a very efficient differentiation and maturation of thymocytes, resulting in a significant T cell population in the periphery. These results demonstrate that CD3 epsilon does not regulate expression of CD3 gamma and delta genes, and underscore the capacity of each prothymocyte to give rise to a large number of mature peripheral T cells.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9885898     DOI: 10.1093/intimm/10.12.1777

Source DB:  PubMed          Journal:  Int Immunol        ISSN: 0953-8178            Impact factor:   4.823


  10 in total

1.  A Rationally Designed Fully Human EGFRvIII:CD3-Targeted Bispecific Antibody Redirects Human T Cells to Treat Patient-derived Intracerebral Malignant Glioma.

Authors:  Patrick C Gedeon; Teilo H Schaller; Satish K Chitneni; Bryan D Choi; Chien-Tsun Kuan; Carter M Suryadevara; David J Snyder; Robert J Schmittling; Scott E Szafranski; Xiuyu Cui; Patrick N Healy; James E Herndon; Roger E McLendon; Stephen T Keir; Gary E Archer; Elizabeth A Reap; Luis Sanchez-Perez; Darell D Bigner; John H Sampson
Journal:  Clin Cancer Res       Date:  2018-04-27       Impact factor: 12.531

2.  Severe combined immunodeficiency caused by deficiency in either the delta or the epsilon subunit of CD3.

Authors:  Geneviève de Saint Basile; Frédéric Geissmann; Elisabeth Flori; Béatrice Uring-Lambert; Claire Soudais; Marina Cavazzana-Calvo; Anne Durandy; Nada Jabado; Alain Fischer; Françoise Le Deist
Journal:  J Clin Invest       Date:  2004-11       Impact factor: 14.808

3.  A PCR-Based Method to Genotype Mice Knocked Out for All Four CD3 Subunits, the Standard Recipient Strain for Retrogenic TCR/CD3 Bone Marrow Reconstitution Technology.

Authors:  Alejandro Ferrer; Adam G Schrum; Diana Gil
Journal:  Biores Open Access       Date:  2013-06

4.  Targeted in vitro and in vivo gene transfer into T lymphocytes: potential of direct inhibition of allo-immune activation.

Authors:  Ashwani K Khanna; Mandeep R Mehra
Journal:  BMC Immunol       Date:  2006-11-10       Impact factor: 3.615

5.  Negative Regulation of Humoral Immunity Due to Interplay between the SLAMF1, SLAMF5, and SLAMF6 Receptors.

Authors:  Ninghai Wang; Peter J Halibozek; Burcu Yigit; Hui Zhao; Michael S O'Keeffe; Peter Sage; Arlene Sharpe; Cox Terhorst
Journal:  Front Immunol       Date:  2015-04-14       Impact factor: 7.561

6.  Proteomic Signatures of Thymomas.

Authors:  Linan Wang; Owen E Branson; Konstantin Shilo; Charles L Hitchcock; Michael A Freitas
Journal:  PLoS One       Date:  2016-11-10       Impact factor: 3.240

7.  Entire CD3ε, δ, and γ humanized mouse to evaluate human CD3-mediated therapeutics.

Authors:  Otoya Ueda; Naoko A Wada; Yasuko Kinoshita; Hiroshi Hino; Mami Kakefuda; Tsuneo Ito; Etsuko Fujii; Mizuho Noguchi; Kiyoharu Sato; Masahiro Morita; Hiromi Tateishi; Kaoru Matsumoto; Chisato Goto; Yosuke Kawase; Atsuhiko Kato; Kunihiro Hattori; Junichi Nezu; Takahiro Ishiguro; Kou-Ichi Jishage
Journal:  Sci Rep       Date:  2017-04-03       Impact factor: 4.379

8.  Progressive loss of CD3 expression after HTLV-I infection results from chromatin remodeling affecting all the CD3 genes and persists despite early viral genes silencing.

Authors:  Haidar Akl; Bassam Badran; Gratiela Dobirta; Germain Manfouo-Foutsop; Maria Moschitta; Makram Merimi; Arsène Burny; Philippe Martiat; Karen E Willard-Gallo
Journal:  Virol J       Date:  2007-09-06       Impact factor: 4.099

9.  Co-potentiation of antigen recognition: A mechanism to boost weak T cell responses and provide immunotherapy in vivo.

Authors:  Michele M Hoffmann; Carlos Molina-Mendiola; Alfreda D Nelson; Christopher A Parks; Edwin E Reyes; Michael J Hansen; Govindarajan Rajagopalan; Larry R Pease; Adam G Schrum; Diana Gil
Journal:  Sci Adv       Date:  2015-10-02       Impact factor: 14.136

10.  GLP toxicology study of a fully-human T cell redirecting CD3:EGFRvIII binding immunotherapeutic bispecific antibody.

Authors:  Patrick C Gedeon; Michael A Streicker; Teilo H Schaller; Gary E Archer; Micheal P Jokinen; John H Sampson
Journal:  PLoS One       Date:  2020-07-31       Impact factor: 3.240

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.